[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100615952":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":20,"locations":21,"responsibleParty":75,"collaborators":20,"id":77,"slug":78,"hasResults":79,"nctId":80,"briefTitle":81,"officialTitle":81,"acronym":20,"eligibilityCriteria":82,"healthyVolunteers":79,"sex":83,"minAge":84,"maxAge":20,"enrollmentInfo":85,"targetDuration":20,"studyType":88,"phases":89,"briefSummary":91,"conditions":92,"keywords":94,"overallStatus":24,"whyStopped":20,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},{"fullName":5,"class":6},"SMED Clinical Research","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"single-cohort","EXPERIMENTAL","Abiraterone 250 mg with food + prednisone, without LHRH analogs or blockers (ADT), achieves castration-level testosterone at 30 days in ≥80-90% of cases.",[13],"Drug: Abiraterone 250 mg with food + prednisone",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Abiraterone 250 mg with food + prednisone","Abiraterone 250 mg with food + prednisone, without LHRH analogs or blockers (ADT), achieves castration-level testosterone at 30 days in ≥80-90% of cases",[9],null,[22,41,58],{"facility":23,"status":24,"city":25,"state":20,"zip":26,"country":27,"countryCode":28,"cosmosGeoPoint":29,"geoPoint":34,"contacts":35},"Hospital Carlos A Durand","RECRUITING","Buenos Aires","5044","Argentina","AR",{"type":30,"coordinates":31},"Point",[32,33],-58.37723,-34.61315,{"lat":33,"lon":32},[36],{"name":37,"role":38,"phone":39,"phoneExt":20,"email":40},"Diego Barreiro, MD","CONTACT","+5491149940794","diegomartinbarreiro@hotmail.com",{"facility":42,"status":43,"city":44,"state":20,"zip":20,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":51,"contacts":52},"Hospital San José","NOT_YET_RECRUITING","Hermosillo","Spain","ES",{"type":30,"coordinates":48},[49,50],-5.47372,40.3349,{"lat":50,"lon":49},[53,57],{"name":54,"role":38,"phone":55,"phoneExt":20,"email":56},"Danny Mena, MD","+527291081110","dmena@theranuks.com",{"name":20,"role":38,"phone":20,"phoneExt":20,"email":56},{"facility":59,"status":24,"city":60,"state":20,"zip":61,"country":45,"countryCode":46,"cosmosGeoPoint":62,"geoPoint":66,"contacts":67},"Instituto Oriente Boliviano","Santa Cruz de la Sierra","10260",{"type":30,"coordinates":63},[64,65],-5.84561,39.33635,{"lat":65,"lon":64},[68,72],{"name":69,"role":38,"phone":70,"phoneExt":20,"email":71},"Lucía Ritcher Lucia Ritcher, MD","+5491149940783","smeclinicalresearch@gmail.com",{"name":73,"role":74,"phone":20,"phoneExt":20,"email":20},"Lucia Ritcher","PRINCIPAL_INVESTIGATOR",{"type":76,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100615952","phase-2-castration-with-abiraterone-250-mg-without-lhrh-analogs-or-blockers-in-patients-with-prostate-cancer-requiring-hormonal-intensification-multicenter-phase-2-100615952",false,"NCT07299292","Castration With Abiraterone 250 mg Without LHRH Analogs or Blockers in Patients With Prostate Cancer Requiring Hormonal Intensification (Multicenter Phase 2)","Inclusion Criteria:\n\n* Age ≥18 years.\n* Histologically confirmed prostate adenocarcinoma.\n* Treated at Hospital Durand (Argentina) or Instituto Oncológico del Oriente Boliviano (Bolivia).\n* Indicated for hormonal intensification (high\u002Fvery high risk candidates for RT, or mHSPC for doublet\u002Ftriplet).\n* No prior ADT.\n* ECOG 0-2; adequate hepatic\u002Frenal function; K+ ≥3.5 mmol\u002FL; controlled BP.\n\nExclusion Criteria:\n\n* Hypersensitivity to ABI\u002Fprednisone; moderate-severe hepatic impairment; uncontrolled hypertension; refractory hypokalemia.\n* Concurrent therapy with strongly contraindicated\u002Finducing drugs affecting ABI levels without possibility of adjustment.","MALE","18 Years",{"count":86,"type":87},60,"ESTIMATED","INTERVENTIONAL",[90],"PHASE2","Hypothesis\n\nThe use of Abiraterone 250 mg with food + prednisone, without LHRH analogs or blockers (ADT), achieves castration-level testosterone at 30 days in ≥80-90% of cases.",[93],"Prostate Cancer (Diagnosis)",[95,96,97,98],"prostate cancer","castration","abiraterone","hormonal intensification","2025-12-09",{"date":101,"type":102},"2025-12-23","ACTUAL",{"date":104,"type":102},"2025-12-01",{"date":106,"type":87},"2027-03-30",{"name":5,"class":6},3]